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Abstract: This paper aims to provide a systematic review of the caries-prevention effect of 
probiotics in human. The hypothesis was that the administration of probiotic strains might 
play a role in caries lesion prevention and in the control of caries-related risk factors. The 
main relevant databases (Medline, Embase) were searched. Quality of the Randomized 
Clinical Trials (RCTs) was classified using the ―Consolidated Standards of Reporting 
Trials‖ (CONSORT) checklist and the Impact Factor (IF) value of each journal was 
recorded. Sixty-six papers were identified, and 23 fulfilled the inclusion criteria. Only three 
studies had caries lesion development as outcome, all the others reported caries risk factors 
as interim evaluation. Using the CONSORT Score, the papers were coded as 4 excellent,  
9 good and 10 poor. The mean IF value recorded was 1.438. Probiotics may play a role as 
antagonistic agent on mutans streptococci (MS), acidogenic/aciduric bacteria that contributes 
to the caries process. In two-thirds of the selected papers, probiotics have demonstrated the 
capacity to reduce MS counts in saliva and/or plaque in short-term. The effect of probiotics 
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on the development of caries lesion seems encouraging, but to date, RCTs on this topic are 
insufficient to provide scientific clinical evidence. 
Key words: probiotics; dental caries; dental caries prevention; cariogenic bacteria; mutans 
streptococci; lactobacilli; plaque pH; plaque acidogenicity 
 
1. Introduction 
Dental caries still remains one of the most common diseases worldwide, although a decline of the 
prevalence has been recorded in western countries [1–3]. The disease is triggered by the interaction 
over time among cariogenic microorganisms (mainly mutans streptococci and lactobacilli), a diet rich 
in fermentable carbohydrates and host factors, like as saliva secretion rate and buffering capacity [4]. 
Mutans streptococci (MS) have been considered for a long time the major pathogens involved in caries 
development. Nevertheless, in recent years, it was described that the microflora on the tooth surface 
changes with caries lesion development, from a predominance of non-mutans streptococci and 
Actinomyces spp. to dominance of MS and other non-mutans bacteria, including lactobacilli and 
Bifidobacterium spp. [5]. 
When sugared food/drinks are supplied frequently, acidogenic and aciduric strains increase 
selectively in the oral environment. These changes, over time, shift the demineralization/remineralization 
balance toward net mineral loss, leading to the caries lesion development [6]. Preventive strategies are 
needed and recommended to control caries risk factors mainly based on dietary changes i.e., 
sweeteners intake reduction and enhancing host resistance [7,8]. Sometimes, antibacterial agents are 
administered in order to reduce cariogenic micro-flora, however, a complete eradication of  
caries-associated microorganisms has proved to be difficult and almost impossible to obtain [9]. 
The World Health Organization has defined probiotics as ―Live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the host‖ [10]. These microorganisms 
belong to the natural human flora in order to survive in the acid environment during transit to  
the intestines. 
Probiotics are recognized to perform several actions in the digestive system as to prevent cellular 
adhesion and invasion of pathogenic bacteria, modify the intestinal environment and modulating the 
local and systemic inflammatory immune response [11]. 
Recent reviews have reported on the use of probiotic strains for the prevention of oral diseases, 
including caries [12,13]. Probiotics are administered to maintain or restore the natural saprophytic 
micro-flora against a pathogen invasion, which is central to the development of the major oral diseases 
(caries and periodontal disease). Probiotic strains administered for oral care are microorganisms 
mainly used to obtain gastrointestinal benefits, so they might not be ideal for the oral environment, 
quite different from the intestinal habitat. The effect of probiotics on dental caries and its related risk 
factors has been evaluated in several experimental studies [14–36], using different strains; 
Lactobacillus rhamnosus GG, L. casei, L. reuteri, L. plantarum, L. brevis CD2, Bifidobacterium spp. etc. 
were proposed and used to obtain caries incidence reduction, mutans streptococci and lactobacilli 
count change, plaque pH control and root caries lesions reversal. 
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Several appropriate vehicles of administration of probiotic strains have been proposed. Dairy 
products supplemented with probiotics are a natural means of oral administration and easily adopted in 
dietary regime for adults and children. However, specifically formulated devices with slow release of 
the microbial strain might be needed in order to oral diseases prevention and control. 
Another uncertain aspect of the probiotic use is whether the probiotics species really are able to 
colonize the oral habitat, and how long the microbial shift was induced [37]. It is well established for 
probiotics in the gastrointestinal tract that they usually colonize for a short time only [38]. Therefore, a 
prolonged administration of the probiotics bacteria seemed is mandatory to improve the benefits  
of the treatment. 
The hypothesis behind this systematic review was that the administration of probiotic strains might 
play a role in the caries lesion prevention and in the control of caries-related risk factors. 
2. Materials and Methods 
2.1. Eligibility Criteria 
The studies included in the present review are Randomized Clinical Trials assessing the in vivo role 
of probiotics administration on caries lesion development and on caries risk factors control (cariogenic 
micro-flora, plaque pH, etc.). Only human studies considering subjects without any stated medical 
condition were considered. Only studies in English were collected, due to the virtual absence of 
research published in other languages as a result of preliminary electronic database searches. All  
in vitro studies, all studies not focusing on probiotics administration for caries prevention and studies 
where probiotics were administered for other reasons were excluded. 
2.2. Search Strategy 
The main important electronic databases were searched: Medline from 01 January 1966 to 15 May 
2013 and Embase from 1973 to 15 May 2013. Two preliminary searches were conducted in March 
2013 in order to obtain an overall idea of findings and to polish search terms (MeSH words) and limits. 
The MeSH Browser was accessed to identify entry terms and compose the final Boolean searches [39]. 
The first step was the association of MeSH terms Dental Caries and Probiotic(s); after that, a 
combination of key words derived from the two previous MeSH terms were searched for a total of  
18 inquiries. The key words used were: Caries, Probiotic Bacteria, Probiotic Lactobacilli, 
Bacteriotherapy, Dental Disease, Oral Health, Oral Streptococci, Cariogenic bacteria, Plaque pH and 
Dental Caries Susceptibility. 
A comparison of the 18 different searches was carried out to delete the repeated studies. Then,  
two authors (M.G.C. and S.M.) examined independently all abstracts of the selected papers. All studies, 
which appeared to meet the inclusion criteria, were obtained in the full text format. The two authors 
assessed the papers independently, to establish whether or not the studies met the inclusion criteria. 
Disagreements were resolved by discussion. If not possible, other authors were consulted. All 
studies meeting the inclusion criteria then went to a validity assessment. Studies rejected at this or 
subsequent stages are reported in the Table 1 of excluded studies with the reasons for exclusion [40–82]. 
For each trial, the following information was recorded: citation details; participants: including 
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demographic characteristics and criteria for inclusion; intervention: including type and duration of 
intervention, duration of follow-up and method of administration. 
Table 1. List of papers not included in the review. 
List of excluded studies 
Reasons for exclusion  
(all different outcome) 
Keller et al. [40] Oral malodour 
Wang et al. [41] Intestinal health 
Allen et al. [42] Diarrhoea 
Iniesta et al. [43] Gingival health 
Slawik et al. [44] Gingival health 
Vandenplas et al. [45] Acute gastroenteritis 
Burton et al. [46] Safety and tolerance  
Krauss-Silva et al. [47] Preterm delivery  
Hummelen et al. [48] Human immunodeficiency virus (HIV) 
Harini et al. [49] Gingival health 
Saxelin et al. [50] Gastrointestinal persistence  
Hummelen et al. [51] Bacterial vaginosis 
Arroyo et al. [52] Infectious mastitis 
Grossi et al. [53] Diarrhoea 
Sierra et al. [54] Intestinal effect 
Sinkiewicz et al. [55] Gingival health 
Mayanagi et al. [56] Gingival health 
Dommels et al. [57] Intestinal persistence 
Ranganathan et al. [58] Kidney disease 
Twetman et al. [59] Gingival health 
Basu et al. [60] Diarrhoea 
Staab et al. [61] Gingival health 
Mao et al. [62] Diarrhoea 
Shimauchi et al. [63] Gingival health 
Marcone et al. [64] Bacterial vaginosis 
Panigrahi et al. [65] Neonatal gut colonization 
Mohan et al. [66] Intestinal health 
Ivory et al. [67] Allergic rhinitis 
Htwe et al. [68] Diarrhoea 
Larsson et al. [69] Bacterial vaginosis 
Hatakka et al. [70] Oral candida 
Basu et al. [71] Diarrhoea 
Henker et al. [72] Diarrhoea 
Sugawara et al. [73] Biliary cancer surgery 
Krasse et al. [74] Gingival health 
Margreiter et al. [75] Diarrhoea 
Olivares et al. [76] Intestinal health 
Sarker et al. [77] Diarrhoea 
Schrezenmeir et al. [78] Acute bacterial infections 
  
Nutrients 2013, 5 2534 
 
Table 1. Cont. 
Reid et al. [79] Bacterial vaginosis 
Morelli et al. [80] Vaginal colonization 
Reid et al. [81] Vaginal colonization 
Arvola et al. [82] Diarrhoea 
2.3. Quality Assessment 
The quality of the trials was assessed through the ―Consolidated Standards of Reporting Trials‖ 
(CONSORT) guidelines [83], using the CONSORT 2010 checklist. The 25-items checklist is focused 
on how the trial was designed, analyzed and interpreted. The quality was classified in three categories 
according to CONSORT score: excellent (≥20 items), good (between 13 and 19 items) and poor  
(≤12 items) [84]. 
The Impact Factor, for each journal where the RCTs were published, was determined from ISI 
Journal Citation Report, 2011 JCR Science Edition [85]. 
3. Results 
Sixty-six (66) papers were identified and assessed, and of these, 23 fulfilled the inclusion criteria 
and they are reported in Tables 2–4 [14–36]. 
No differences were observed between the two main databases used. Selected papers were divided 
between those performed on children/adolescents and those on adults. All studies utilized parallel arms 
with intervention and a placebo/control or a crossover design. The sample sizes were generally small 
or medium, and the majority of them (80%) were short-term interventions (between 10 and 42 days). 
Different vehicles for the administration and different dosage of probiotics were used. The quality of 
published papers recorded using the Consort Score was: 4 excellent, 9 good and 10 poor. All papers, 
except two [19,23], were published on Journals with positive IF with a mean value of 1.438. 
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Table 2. Studies with caries risk factors as outcome (children/adolescents). 
Reference  
Study design 
Outcome(s) Subjects Age Strain (Concentration) 
Delivery System/ 
Treatment Duration 
Groups Results 
Consort 
score 
IF score 
Taipale et al.,  
2013 [14] 
MS in plaque  
(plate culturing) 
106 children  
(4 years) 
Bifidobacterium animalis 
subsp.  
lactis BB-12  
(1010 CFU/mL) 
Tablets in slow-release pacifier or  
spoon twice daily/22–23 months 
A: Probiotic  
B: Xylitol  
C: Sorbitol 
No statistically  
significant MS differences 
among groups 
excellent 2.328 
Campus et al.,  
2013 [15] 
MS in saliva and 
plaque pH  
(plate culturing) 
191 children  
(6–8 years) 
Lactobacillus brevis  
CD2 (2 × 109/g) 
Lozenges twice a day/6 weeks 
A: Probiotic  
B: Placebo 
Statistically significant 
decrease in MS and increase  
in plaque pH in group A 
excellent 2.364 
Juneja et al.,  
2012 [16] 
MS in saliva  
(chair-side tests) 
40 children  
(12–15 years) 
Lactobacillus rhamnosus 
hct 70  
(2.34 × 109 CFU/day) 
Milk twice daily/3 weeks 
A: Milk  
B: Milk + Probiotic 
Statistically significant 
reduction in MS immediately 
after consumption and after  
3 week follow-up in group A 
poor 0.444 
Taipale et al.,  
2012 [17] 
MS in plaque and 
Lb and yeasts in 
mucosa/teeth  
(plate culturing) 
106 infants  
(1 month) 
Bifidobacterium animalis 
subsp.  
lactis BB-12  
(1010 CFU/mL) 
Tablets in slow-release pacifier  
or spoon twice daily/months 
A: Probiotic  
B: Xylitol  
C: Sorbitol 
MS colonization statistically 
significant differ, lactobacilli 
and yeasts not differ  
among groups 
excellent 2.328 
Singh et al.,  
2011 [21]  
cross-over study 
MS and Lb in 
saliva  
(chair-side tests) 
40 children  
(12–14 years) 
Bifidobacterium lactis  
Bb-12 ATCC27536 and 
Lactobacillus acidophilus 
La-5 (106 CFU/g) 
Ice-cream/10 days 
A: Ice-cream  
B: Ice-cream/probiotics 
Statistically significant 
reduction in MS in group B, 
but no significant  
effect on lactobacilli 
good 1.066 
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Table 2. Cont. 
Aminabadi et al., 
2011 [22] 
MS in saliva  
(plate culturing) 
105 children  
(6–12 years) 
Lactobacillus  
rhamnosus GG  
(2 × 108 CFU/mL) 
Yogurt/3 weeks  
(chlorhexidine mouthrinse 2 weeks) 
A: Chlorhexidine  
B: Probiotic  
C: Chlorhexidine,  
than probiotic  
Statistically significant MS 
decrease immediately after 
probiotic use in group B; 
recolonization during the  
5 consecutive weeks. In 
group C a statistically 
significant MS reduction that 
enhances during the  
5 consecutive weeks 
good 2.328 
Jindal et al.,  
2011 [23] 
MS in saliva  
(plate culturing) 
150 children  
(7–14 years) 
Lactobacillus rhamnosus, 
Bifidobacterium longum, 
Saccharomyces cereviasae 
(1.25 billion)  
Bacillus coagulans  
(150 million) 
Powders (dissolved in water and  
used as mouthrinse)/14 days 
A: Placebo  
B: L. rhamnosus, B. 
longum and  
S. cereviasae  
C: B. coagulans 
Statistically significant MS 
reduction in groups B and C 
good - 
Lexner et al.,  
2010 [26] 
MS and Lb in 
saliva  
(plate culturing) 
18 adolescents  
(13–17 years) 
Lactobacillus rhamnosus 
LB21 (107 CFU/mL) 
Milk once daily/2 weeks 
A: Probiotic  
B: Placebo  
No statistically significant  
MS reduction and Lb  
poor 0.539 
Cildir et al.,  
2009 [27]  
cross-over study 
MS and Lb in 
saliva  
(chair-side tests) 
24 adolescents with 
fixed orthodontics  
(12–16 years) 
Bifidobacterium animalis 
subsp. lactis DN 173010  
(2 × 108 CFU/g) 
Yogurt once daily/2 weeks 
A: Probiotic  
B: Placebo  
Statistically significant MS 
reduction in group A and no 
significant Lb alterations  
poor 0.975 
Stec s n-Blicks  
et al., 2009 [28] 
MS and Lb in 
plaque  
(plate culturing) 
248 children  
(1–4 years) 
Lactobacillus rhamnosus 
LB21 (107 CFU/mL) 
Milk/21 months 
A: Probiotic/fluoride  
B: Placebo 
No statistically significant 
changes in MS and Lb  
good 2.462 
Näse et al.,  
2001 [36] 
MS in plaque and 
saliva  
(chair-side tests) 
594 children  
(1–6 years) 
Lactobacillus rhamnosus 
GG, ATCC 53103  
(5–10 × 105 CFU/mL) 
Milk five daily/7 months 
A: Milk/probiotic  
B: Milk 
Statistically significant MS 
reduction in group A 
excellent 1.667 
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Table 3. Studies with caries risk factors as outcome (adults). 
Reference  
Study design 
Outcome(s) Subjects Age 
Strain  
(Concentration) 
Delivery System/ 
Treatment 
Duration 
Groups Results Consort score IF score 
Marttinen et al., 
2012 [18]  
Cross-over study 
Plaque 
acidogenicity, MS 
and Lb in plaque  
(plate culturing) 
13 adults  
(mean 25 years) 
Lactobacillus 
rhamnosus GG or 
Lactobacillus reuteri  
(196 million 
CFU/tablet) 
Tablet twice a 
day/2 weeks 
A: LGG  
B: L. reuteri  
No changes in plaque 
acidogenicity. MS remained 
stable, while Lb increased in the 
L. reuteri group, but not  
in the LGG group 
good 2.364 
Keller & 
Twetman,  
2012 [19]  
Cross-over study  
MS and  
Lb in saliva  
(chair-side tests)  
Lactatic Acid 
production in 
plaque  
18 adults  
(mean 26 years) 
Lactobacillus reuteri 
(DSM 17938 and 
ATCC PTA 5289)  
(2 × 108 CFU/tablet) 
Tablets three times 
a day/2 weeks  
A: L. reuteri  
B: Placebo 
No statistically significant MS 
change; Lb increased 
significantly in group A.  
No significant differences in 
Lactatic Acid production  
good - 
Keller et al., 
2012 [20]  
Inhibiting 
regrowth of 
salivary MS after 
full-mouth 
disinfection  
(chair-side tests) 
62 adults  
(mean 23 years) 
Lactobacillus reuteri 
(DSM 17938 and 
ATCC PTA 5289)  
(2 × 108 CFU/tablet) 
Tablets twice 
daily/6 weeks 
A: Probiotics  
B: Placebo 
L. reuteri did not seem to affect 
or delay the regrowth of MS  
good 2.328 
Petersson et al., 
2011 [24] 
MS and  
Lb in saliva  
(chair-side tests) 
and plaque  
(plate culturing) 
160 adults  
(58–84 years) 
Lactobacillus 
rhamnosus LB21  
(107 CFU/mL) 
Milk once daily/ 
15 months 
A: Placebo  
B: Fluoride/ 
probiotic  
C: Probiotic  
D: Fluoride 
Lower prevalence of MS and Lb, 
but not statistically significant 
good 1.066 
Chuang et al., 
2011 [25] 
MS and Lb in 
saliva (chair-side 
tests) and  
buffer capacity 
(Dentobuff strip) 
80 adults  
(20–26 years) 
Lactobacillus 
paracasei  
GMNL-33  
(3 × 108 CFU/mL) 
Tablets three times 
per day/2 weeks 
A: Probiotics  
B: Xylitol 
No statistically significant 
differences in MS and Lb and 
buffer capacity. MS reduction 
intra probiotics group 
poor 2.364 
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Table 3. Cont. 
Caglar. et al., 
2008 [29]  
Cross-over study 
MS and  
Lb in saliva  
(chair-side tests)  
24 adults  
(mean 20 years) 
Bifidobacterium lactis 
Bb-12 (107 CFU/g) 
Ice-cream once 
daily/10 days 
A: Probiotic  
B: Placebo  
Statistically significant MS 
reduction in group A; salivary  
Lb levels unaltered 
poor 1.095 
Caglar et al., 
2008 [30] 
MS and  
Lb in saliva  
(chair-side tests) 
20 women  
(mean 20 years) 
Lactobacillus reuteri 
ATCC 55730: ATCC 
PTA 5289 10:1  
(1.1 × 108 CFU) 
Lozenge once 
daily/10 days 
A: Probiotic  
B: Placebo 
Statistically significant MS 
reduction in group A;  
Lb unaltered 
poor 1.072 
Caglar et al., 
2007 [31] 
MS and  
Lb in saliva  
(chair-side tests) 
80 adults  
(21–24 years) 
Lactobacilli reuteri 
ATCC and 
Lactobacilli reuteri 
ATCC PTA 5289  
(108 CFU/gum) 
chewing gums 
three times daily/ 
3 weeks 
A: Probiotics  
B: Xylitol  
C: Probiotics/xylitol  
D: Placebo 
Statistically significant MS 
reduction in group A,  
B and C; Probiotic + xylitol not 
enhance the efficacy. 
poor 1.956 
Caglar et al., 
2006 [32] 
MS and Lb  
in saliva  
(chair-side tests) 
120 adults  
(21–24 years) 
Lactobacillus reuteri 
ATCC 55730  
(108 CFU/straw  
or tablet) 
Water or tablet 
once daily/3 weeks 
A: Water/probiotic  
B: Placebo water  
C: Tablet/probiotic  
D: Placebo tablet 
Statistically significant MS 
reduction in groups A and C; 
similar but non-significant  
trend for Lb  
poor 1.017 
Caglar et al., 
2005 [33]  
Cross-over study 
MS and  
Lb in saliva  
(chair-side tests) 
26 adults  
(21–24 years) 
Bifidobacterium  
DN-173 010  
(7 × 107 CFU/g) 
Yogurt once 
daily/2 weeks 
A: Probiotic  
B: Placebo  
Statistically significant MS 
reduction in group A; similar but 
non-significant trend for Lb  
poor 0.783 
Montalto et al., 
2004 [34] 
MS and  
Lb in saliva  
(chair-side tests) 
35 adults  
(23–37 years) 
L. sporogens,  
L. bifidum,  
L. bulgaricus,  
L. termophilus,  
L. acidophilus,  
L. casei,  
L. rhamnosus  
(1.88 × 109 live 
cells/day) 
Liquid and 
capsule/45 days 
A: Probiotics 
capsules placebo in 
liquid  
B: Liquid probiotics 
placebo in capsules  
C: Placebo in both 
liquid and capsule 
Statistically significant Lb 
increase in groups A and B.  
MS not significantly modified. 
poor 1.473 
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Ahola et al., 
2002 [35] 
MS, Lb and  
yeasts in saliva 
(chair-side tests) 
and buffer 
capacity  
(Dentobuff strip) 
74 young adults 
(18–35 years) 
Lactobacillus 
rhamnosus GG ATCC 
53103 (1.9 × 107 
CFU/g) and 
Lactobacillus 
rhamnosus LC 705 
(1.2 × 107 CFU/g) 
Cheese five daily/ 
3 weeks 
A: Probiotics  
B: Placebo 
No statistically significant 
differences in MS and Lb after 
the intervention; during  
the post-treatment period  
(3 weeks) a significantly 
reduction of the two species in 
group A. No statistically 
significant differences in yeast 
and buffer capacity  
good 1.047 
Table 4. Studies with caries lesion development as outcome. 
Reference Outcome(s) Subjects 
Strain 
(Concentration) 
Delivery System/ 
Treatment Duration 
Groups Results Consort score IF score 
Taipale et al.,  
2013 [14] 
Caries 
increment 
(ICDAS 
index) 
106 children  
(4 years) 
Bifidobacterium 
animalis subsp.  
lactis BB-12  
(1010 CFU/mL) 
Tablets in  
slow-release pacifier or 
spoon twice daily/ 
22–23 months 
A: Probiotic  
B: Xylitol  
C: Sorbitol 
No differences in the 
occurrence  
of enamel caries 
excellent 2.328 
Petersson et al.,  
2011 [24] 
Root Caries 
Index (RCI) 
and Electric 
Resistance 
Measurements 
(ERM) 
160 adults  
(58–84 years) 
Lactobacillus 
rhamnosus LB21 (107 
CFU/mL) 
Milk once daily/ 
15 months 
A: Placebo  
B: 
Fluoride/probiotic 
C: Probiotic  
D: Fluoride 
Higher numbers of RCI 
reversals in groups B, C and 
D. Mean ECM values 
increased significantly in 
groups A, B and C 
good 1.066 
Stec s n-Blicks  
et al., 2009 [28] 
Caries 
increment 
(dmfs index) 
248 children  
(1–4 years) 
Lactobacillus 
rhamnosus LB21  
(107 CFU/mL) 
Milk once  
daily/21 months 
A: Probiotic/ 
fluoride  
B: Placebo 
Statistically significant 
difference in caries increment 
in group A 
good 2.462 
 
Nutrients 2013, 5 2540 
 
3.1. Probiotics and Caries Prevention in Children/Adolescents 
Eleven studies were evaluated [14–17,21–23,26–28,36]. Only one study was performed to verify 
the effect of the early administration of probiotics (Bifidobacterium animalis subsp. lactis BB-12) on 
the oral colonization of mutans streptococci (MS) in 106 infants from a low-caries population [17]. 
Subjects received probiotic bacteria, xylitol or sorbitol (polyol 100–300 mg) from the age of 1–2 months to 
the age of 2 years, twice a day. The MS concentration in plaque of the mothers at the start of the study 
was high and similar in all subjects, without significant differences. At the end of the study, children 
showed a rather low MS colonization percentage, with a statistically significant difference among 
groups. At the age of 4 years, the same children were re-evaluated to assess the MS level in plaque and 
the occurrence of dental caries in deciduous teeth [14]. No differences were observed for both 
parameters among the three groups. 
Otherwise, nine studies were carried out to verify the effect of probiotics strains on MS levels in 
saliva and/or dental plaque, using different vehicle [15,16,21–23,26–28,36]. Only two studies did not 
demonstrate any change in SM level [26,28]. 
The effect of milk containing L. rhamnosus on MS counts was evaluated in four papers (two short 
and two long-term studies). In the short-term studies [16,26], the effect of milk containing 
Lactobacillus rhamnosus (hct 70 or LB21) for few weeks was registered in small groups of 
adolescents. The difference in post treatment regarding MS count between test and control group was 
not statistically significant, while the difference in follow-up was highly significant [16]. No 
statistically significant differences in SM were recorded in subjects who received milk with probiotic 
compared to subjects using milk without probiotic [26]. In the long-term studies [28,36], L. rhamnosus 
was administered for several months (7 and 21 months respectively). Statistically significant reductions 
were recorded with Lactobacillus rhamnosus GG, ATCC use [36], while no statistically significant 
changes were observed in SM counts in subjects receiving Lactobacillus rhamnosus LB21 [28]. 
Two studies were performed with yogurt as probiotics vehicle [22,27]. The effect of the 
administration of yogurt containing Lactobacillus rhamnosus GG for three weeks in 105 children was 
evaluated with a significant decrease in SM count immediately after probiotics use alone, but 
recolonization was described during the five consecutive weeks [22]. Pre-treatment with chlorhexidine 
produced a statistically significant reduction in salivary SM counts that enhances during the five 
consecutive weeks. A double-blind, crossover study was carried out on 24 healthy adolescents, 
undergoing orthodontic treatment, with the aim to assess the effect of yogurt containing 
Bifidobacterium animalis subsp. lactis DN-173010 administered once daily [27]. Statistically 
significant reduction of MS was recorded after probiotic yogurt consumption. 
One study used ice-cream as probiotic vehicle [21]; a combination of Bifidobacterium lactis Bb-12 
and Lactobacillus acidophilus La-5 was evaluated in 40 adolescents. Significant reduction in salivary 
MS scores was reported after consumption of the probiotic compared to baseline. 
One study was performed using lozenges as probiotic vehicle. The effect of lozenges containing 
Lactobacillus brevis CD2 administered for six weeks was evaluated in 191 high caries risk children [15]. 
A statistically significant reduction of the cariogenic microorganism was recorded. 
One study used two powders as probiotic vehicle in 150 children aged 7–14 years, containing the 
first Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces cereviasae and the second 
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Bacillus coagulans, and compared them to a placebo powder [23]. Powders dissolved in 20 mL of 
water were used as a mouth rinse for one minute for 14 consecutive days. Data analysis showed a 
statistically significant reduction in MS counts in both probiotics groups. 
Five studies of the ten reported above, investigated the effect of the probiotics strain on Lb level 
also [17,21,26–28]. In all studies, a statistically significant change in Lb counts in saliva and/or plaque 
was not observed. Moreover, one study evaluated the effect of the probiotic on oral yeasts, failing to 
prove any statistically effect [17]. The effect of probiotics on plaque pH modification after a rinse with 
a 10% sugared solution was investigated and plaque acidogenicity resulted significantly lower in 
subjects that have used probiotic lozenges [15]. Two studies evaluated the probiotic effect on caries 
lesion development [14,28]. A statistically significant difference in caries increment was recorded only 
in one paper in subjects who received probiotic and fluoride compared to subjects who received 
placebo milk [28]. 
3.2. Probiotics and Caries Prevention in Adults 
Twelve studies were selected [18–20,24,25,29–35]: all of them investigated the effects of probiotic 
administration on MS counts in plaque and/or saliva and six demonstrated a MS reduction. 
Caglar and co-workers [29–33], performed several studies on the change of salivary MS 
concentration after the use of several probiotics (Bifidobacterium lactis Bb-12, Lactobacillus reuteri 
ATCC 55730 and ATCC PTA 5289, Bifidobacterium DN-173 010) using different vehicles (ice-cream, 
chewing-gum, water, yogurt and tablets). MS concentrations decrease significantly in all studies. 
No statistically significant differences in MS counts were recorded immediately after consumption 
of cheese containing Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC 705, but a 
significant reduction was reported three weeks after the experimental period [35]. 
Conversely, the other six of the twelve studies did not reveal an effect of probiotics administration 
on MS counts [18–20,24,25,34]. Four short-term studies were performed using tablets containing 
Lactobacillus rhamnosus or Lactobacllus reuteri; MS counts remained stable after the administration 
of both probiotics twice a day for two weeks in 13 adults [18]. No significant differences were also 
observed after the use for two weeks of Lactobacillus reuteri on MS counts in 18 adults [19], and 
using the same strains after full mouth disinfection with chlorhexidine on 62 adults on regrow of  
MS [20]. Tablets containing Lactobacillus paracasei GMNL-33 were unsuccessfully administered to 
80 young adults [25]. One long-term study evaluated the effect of Lactobacillus rhamnosus LB21 
delivered in milk on MS count in saliva and supra-gingival plaque in 160 older adults for 15 months [24]. 
No statistically significant reduction in MS count was registered. Results from a study utilizing several 
strains of Lactobacillus spp. in liquid and capsules form in 35 adults revealed no significantly MS 
count reduction [34]. 
Moreover, ten studies of the twelve reported above, investigated the effect of the probiotics strain 
on Lb level in saliva and/or plaque [18,19,25,29,30–35]. Eight studies failed to prove any effect on Lb 
counts and two studies demonstrated a statistically significant change in Lb counts [19,35]. 
Two studies evaluated also the effect of probiotics on plaque acidogenicity, but no significant 
changes were found [18,19]. Two studies investigated the effect on buffer capacity failing to demonstrate 
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a statistically significant difference on it [25,35]. One of these did not demonstrate an effect on oral 
yeast yet [35]. 
4. Discussion 
The role of the administration of probiotic strains in caries prevention was the aim of this systematic 
review. Results described by various research groups were encouraging [15–17,21–24,27,29–33,35,36], 
but the scientific evidence is still unclear and often not very high. The main goal for the use of 
probiotics in caries prevention is to replace and displace cariogenic bacteria, mainly mutans 
streptococci, with noncariogenic bacteria [13]. 
Most clinical trials reviewed had a small sample size and reported caries risk factors as intermediate 
or surrogate endpoints, which limited the conclusions about the real efficacy of probiotics administration 
in caries lesion prevention. From the analysis of the RCTs selected, it reasonable to affirm that 
probiotic strains may play a role as antagonistic agent on cariogenic bacteria. In the two-thirds of the 
selected papers, probiotics have demonstrated the capacity to reduce MS counts in saliva and/or plaque 
regardless of the product or strain used. However, this effect is variable and probably short-lasting. In 
addition, MS are no longer considered the main cariogenic bacteria involved in the caries progress, 
since the important role of non-mutans acidogenic and aciduric bacteria was clarified [5]. Different 
results are reported on the effect of probiotics on lactobacilli counts. From the fourteen studies that 
evaluated the changes of this interim outcome, just two reported a positive result [19,35]. The other 
interim outcomes considered (yeasts and plaque acidogenicity) were investigated in few studies and 
the results are unclear. Only three selected papers [14,24,28], two performed on children and another 
one on adults/elderly samples, had caries lesion development as outcome; two studies reported a 
statistically significant difference in caries increment after 15/21 months of probiotics use [24,28]. 
Several mechanisms of action for probiotic are described in literature, same of them still  
not fully understood. Several local and systemic effects are describing, including adhesion,  
co-aggregation, competitive inhibition, production of organic acids and bacteriocin-like compounds 
and immune-modulation [86]. However, probiotic bacteria are not able to colonize oral cavity 
permanently [29], so a continuous regular, almost daily intake is required. This may be a compliance 
aspect to be considered. 
In eleven selected papers, a dairy product (milk, cheese, yogurt and ice-cream) was used as delivery 
vehicle for probiotics [16,21,22,24,26–29,35,36]. These non-sweetened products are known to possess 
caries preventive effects related to a natural high contents in calcium and phosphate that enhance 
remineralization of hard oral tissues and contrast acids produced by cariogenic bacteria after sugared 
foods and drinks intake [13]. Only one selected paper used chewing gums as delivery vehicle [31]. The 
use of non-sugared chewing gum has been considered useful for dental health, since it reduces plaque 
acidogenicity and increases enamel remineralization, enhancing salivary flow rate [87]. The remaining 
eleven papers used as probiotic vehicle products (lozenges, tablets, powders) without any reported 
preventive effects themselves [14,15,17–20,23,25,30,32,34]. 
One study evaluated the combined effect of probiotics and fluoride on cariogenic bacteria and 
caries lesion increment. No statistically significant differences were recorded between the group using 
probiotics alone and those using probiotic and fluoride together [24]. Another paper studied the 
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combined effect of probiotics and low dosage of xylitol on cariogenic microorganisms [31], but no 
statistically significant differences were noted compared to probiotics alone. Finally only one study has 
investigated the effect of probiotic on MS counts after chlorhexidine mouthwash disinfection [22].  
Pre-treatment with chlorhexidine produced a long-lasting reduction in salivary SM compared to 
probiotics alone. 
It is interesting to note that up to day none products have successfully approved by the European 
Food Safety Authority (EFSA) [88,89]. 
A theoretical risk of the probiotic assumption is the increase of caries risk due to the capacity of 
probiotic strains to form biofilm and produce acids, but this aspect was not taken into consideration by 
any papers. 
Two approaches have been used to assess the quality of RCTs in the present review: the CONSORT 
checklist and the journal Impact Factor. A significant association between the CONSORT score and 
the impact factor was reported [90]. 
The CONSORT checklist takes into account 25 important methodological items, providing an 
accurate evaluation of the methodological correctness with which the study was planned and carried 
out. From the analysis of the checklists of the selected papers, the main deficiencies observed were the 
lack of information on methods to define the hypothesis, the sample size calculation, the absence of 
data on the results of estimated effects size and their precision. These methodological weaknesses 
reduce the validity of studies and the interpretation of the results may lead to biased findings. 
Moreover, few studies reported correctly the results of the RCTs not taking into account other sources 
of bias. In general, the quality of reporting of RCTs was quite low, with half of all studies scoring as 
poor with the exception of three studies that were scored as excellent. These results are similar to those 
reported of other systematic review [13], but it is possible to observe a progressive improvement in the 
scientific evidence of the effect of probiotic on caries prevention. 
The journal impact factor has been used widely as a quality measure of the published papers [91]. 
All selected studies except two were published in journals with impact factor and all except one in 
dental journal [34]. The mean value of impact factors of the selected studies (1.438) might seem low 
when compared with IF of journals from other areas of medicine. However, the mean impact factor 
value of the 81 impacted dental journals is quite low (1.455—range 0.037–3.961), with the journals 
with the highest IF values dedicated to other topic of dentistry, different from caries prevention. 
Therefore, the mean IF value recorded in the present review has to be considered a quite good score. 
5. Conclusions 
The use of probiotic strains for caries prevention showed promising results even if only few studies 
have demonstrated clear clinical outcomes. Therefore, the scientific evidence is still poor. A 
continuous regular almost daily intake is probably required; this maybe a compliance aspect to be 
considered. However, for all products effective in caries prevention (i.e., fluoride and chlorhexidine) a 
frequent intake is required, so a possible way of administration could be to insert probiotic in other 
daily preventive products like toothpaste. 
  
Nutrients 2013, 5 2544 
 
Conflict of Interest 
The authors declare no conflict of interest. The authors declare that no support was supplied by 
probiotic companies. 
References 
1. Campus, G.; Solinas, G.; Cagetti, M.G.; Senna, A.; Minelli, L.; Majori, S.; Montagna, M.T.; 
Reali, D.; Castiglia, P.; Strohmenger, L. National pathfinder survey of 12-year-old children’s oral 
health in Italy. Caries Res. 2007, 41, 512–517. 
2. Campus, G.; Solinas, G.; Strohmenger, L.; Cagetti, M.G.; Senna, A.; Minelli, L.; Majori, S.; 
Montagna, M.T.; Reali, D.; Castiglia, P. Collaborating Study Group. National pathfinder survey 
on children’s oral health in Italy: Pattern and severity of caries disease in 4-year-olds. Caries Res. 
2009, 43, 155–162. 
3. Marja-Leena, M.; Paivi, R.; Sirkka, J.; Ansa, O.; Matti, S. Childhood caries is still in force: A  
15-year follow-up. Acta Odontol. Scand. 2008, 66, 189–192. 
4. Selwitz, R.H.; Ismail, A.I.; Pitts, N.B. Dental caries. Lancet 2007, 369, 51–59. 
5. Takahashi, N.; Nyvad, B. The role of bacteria in the caries process: Ecological perspectives.  
J. Dent. Res. 2011, 90, 294–303. 
6. Eliasson, L.; Carlén, A.; Almståhl, A.; Wikström, M.; Lingström, P. Dental plaque pH and  
micro-organisms during hyposalivation. J. Dent. Res. 2006, 85, 334–338. 
7. Milgrom, P.; Söderling, E.M.; Nelson, S.; Chi, D.L.; Nakai, Y. Clinical evidence for polyol 
efficacy. Adv. Dent. Res. 2012, 24, 112–116. 
8. Petersen, P.E.; Lennon, M.A. Effective use of fluorides for the prevention of dental caries in the 
21st century: The WHO approach. Community Dent. Oral Epidemiol. 2004, 32, 319–321. 
9. Zero, D.T. Dentifrices, mouthwashes and remineralization/caries arrestment strategies. BMC Oral 
Health 2006, 6 (Suppl. 1), 9. 
10. World Health Organization. Available online: http://www.who.int/foodsafety/publications/ 
fs_management/en/probiotics.pdf (accessed on 17 April 2013). 
11. Floch, M.H.; Walker, W.A.; Madsen, K.; Sanders, M.E.; Macfarlane, G.T.; Flint, H.J.;  
Dieleman, L.A.; Ringel, Y.; Guandalini, S.; Kelly, C.P.; et al. Recommendations for probiotic 
use—2011 update. J. Clin. Gastroenterol. 2011, 4, S168–S171. 
12. Saha, S.; Tomaro-Duchesneau, C.; Tabrizian, M.; Prakash, S. Probiotics as oral health 
biotherapeutics. Expert Opin. Biol. Ther. 2012, 12, 1207–1220. 
13. Twetman, S.; Keller, M.K. Probiotics for caries prevention and control. Adv. Dent. Res. 2012, 24, 
98–102. 
14. Taipale, T.; Pienihäkkinen, K.; Alanen, P.; Jokela, J.; Söderling, E. Administration of 
Bifidobacterium animalis subsp. lactis BB-12 in early childhood: A post-trial effect on caries 
occurrence at four years of age. Caries Res. 2013, 47, 364–372. 
15. Campus, G.; Cocco, F.; Carta, G.; Cagetti, M.G.; Simark-Mattson, C.; Strohmenger, L.; 
Lingström, P. Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk 
schoolchildren. Clin. Oral Investig. 2013, doi:10.100.7/s00784-013-09-80-9. 
Nutrients 2013, 5 2545 
 
16. Juneja, A.; Kakade, A. Evaluating the effect of probiotic containing milk on salivary mutans 
streptococci levels. J. Clin. Pediatr. Dent. 2012, 37, 9–14. 
17. Taipale, T.; Pienihäkkinen, K.; Salminen, S.; Jokela, J.; Söderling, E. Bifidobacterium animalis 
subsp. lactis BB-12 administration in early childhood: A randomized clinical trial of effects on 
oral colonization by mutans streptococci and the probiotic. Caries Res. 2012, 46, 69–77. 
18. Marttinen, A.; Haukioja, A.; Karjalainen, S.; Nylund, L.; Satokari, R.; Öhman, C.; Holgerson, P.; 
Twetman, S.; Söderling, E. Short-Term consumption of probiotic lactobacilli has no effect on acid 
production of supragingival plaque. Clin. Oral Investig. 2012, 16, 797–803. 
19. Keller, M.K.; Twetman, S. Acid production in dental plaque after exposure to probiotic bacteria. 
BMC Oral Health 2012, 12, 44. 
20. Keller, M.K.; Hasslöf, P.; Dahlén, G.; Stecksén-Blicks, C.; Twetman, S. Probiotic supplements 
(Lactobacillus reuteri DSM 17938 and ATCC PTA 5289) do not affect regrowth of mutans 
streptococci after full-mouth disinfection with chlorhexidine: A randomized controlled multicenter 
trial. Caries Res. 2012, 46, 140–146. 
21. Singh, R.P.; Damle, S.G.; Chawla, A. Salivary mutans streptococci and lactobacilli modulations 
in young children on consumption of probiotic ice-cream containing Bifidobacterium lactis Bb12 
and Lactobacillus acidophilus La5. Acta Odontol. Scand. 2011, 69, 389–394. 
22. Aminabadi, N.A.; Erfanparast, L.; Ebrahimi, A.; Oskouei, S.G. Effect of chlorhexidine pretreatment 
on the stability of salivary lactobacilli probiotic in six- to twelve-year-old children: A randomized 
controlled trial. Caries Res. 2011, 45, 148–154. 
23. Jindal, G.; Pandey, R.K.; Agarwal, J.; Singh, M. A comparative evaluation of probiotics on 
salivary mutans streptococci counts in Indian children. Eur. Arch. Paediatr. Dent. 2011, 12,  
211–215. 
24. Petersson, L.G.; Magnusson, K.; Hakestam, U.; Baigi, A.; Twetman, S. Reversal of primary root 
caries lesions after daily intake of milk supplemented with fluoride and probiotic lactobacilli in 
older adults. Acta Odontol. Scand. 2011, 69, 321–327. 
25. Chuang, L.C.; Huang, C.S.; Ou-Yang, L.W.; Lin, S.Y. Probiotic Lactobacillus paracasei effect on 
cariogenic bacterial flora. Clin. Oral Investig. 2011, 15, 471–476. 
26. Lexner, M.O.; Blomqvist, S.; Dahlén, G.; Twetman, S. Microbiological profiles in saliva and 
supragingival plaque from caries-active adolescents before and after a short-term daily intake of 
milk supplemented with probiotic bacteria—A pilot study. Oral Health Prev. Dent. 2010, 8,  
383–388. 
27. Cildir, S.K.; Germec, D.; Sandalli, N.; Ozdemir, F.I.; Arun, T.; Twetman, S.; Caglar, E. 
Reduction of salivary mutans streptococci in orthodontic patients during daily consumption of 
yoghurt containing probiotic bacteria. Eur. J. Orthod. 2009, 31, 407–411. 
28. Stecksén-Blicks, C.; Sjöström, I.; Twetman, S. Effect of long-term consumption of milk 
supplemented with probiotic lactobacilli and fluoride on dental caries and general health in 
preschool children: A cluster-randomized study. Caries Res. 2009, 43, 374–381. 
29. Caglar, E.; Kuscu, O.O.; Selvi Kuvvetli, S.; Kavaloglu Cildir, S.; Sandalli, N.; Twetman, S.  
Short-term effect of ice-cream containing Bifidobacterium lactis Bb-12 on the number of salivary 
mutans streptococci and lactobacilli. Acta Odontol. Scand. 2008, 66, 154–158. 
Nutrients 2013, 5 2546 
 
30. Caglar, E.; Kuscu, O.O.; Cildir, S.K.; Kuvvetli, S.S.; Sandalli, N. A probiotic lozenge 
administered medical device and its effect on salivary mutans streptococci and lactobacilli. Int. J. 
Paediatr. Dent. 2008, 18, 35–39. 
31. Caglar, E.; Kavaloglu, S.C.; Kuscu, O.O.; Sandalli, N.; Holgerson, P.L.; Twetman, S. Effect of 
chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and 
lactobacilli. Clin. Oral Investig. 2007, 11, 425–429. 
32. Caglar, E.; Cildir, S.K.; Ergeneli, S.; Sandalli, N.; Twetman, S. Salivary mutans streptococci and 
lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by 
straws or tablets. Acta Odontol. Scand. 2006, 64, 314–318. 
33. Caglar, E.; Sandalli, N.; Twetman, S.; Kavaloglu, S.; Ergeneli, S.; Selvi, S. Effect of yogurt with 
Bifidobacterium DN-173 010 on salivary mutans streptococci and lactobacilli in young adults. 
Acta Odontol. Scand. 2005, 63, 317–320. 
34. Montalto, M.; Vastola, M.; Marigo, L.; Covino, M.; Graziosetto, R.; Curigliano, V.; Santoro, L.; 
Cuoco, L.; Manna, R.; Gasbarrini, G. Probiotic treatment increases salivary counts of lactobacilli: 
A double-blind, randomized, controlled study. Digestion 2004, 69, 53–56. 
35. Ahola, A.J.; Yli-Knuuttila, H.; Suomalainen, T.; Poussa, T.; Ahlström, A.; Meurman, J.H.; 
Korpela, R. Short-term consumption of probiotic-containing cheese and its effect on dental caries 
risk factors. Arch. Oral Biol. 2002, 47, 799–804. 
36. Näse, L.; Hatakka, K.; Savilahti, E.; Saxelin, M.; Pönkä, A.; Poussa, T.; Korpela, R.; Meurman, J.H. 
Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk 
on dental caries and caries risk in children. Caries Res. 2001, 35, 412–420. 
37. Rao, Y.; Lingamneni, B.; Reddy, D. Probiotics in oral health—A review. J. N. J. Dent. Assoc. 
2012, 83, 28–32. 
38. Ravn, I.; Dige, I.; Meyer, R.L.; Nyvad, B. Colonization of the oral cavity by probiotic bacteria. 
Caries Res. 2012, 46, 107–112. 
39. National Library of Medicine. Available online: http://www.nlm.nih.gov/mesh/MBrowser.html.22 
(accessed on 14 February 2013). 
40. Keller, M.K.; Bardow, A.; Jensdottir, T.; Lykkeaa, J.; Twetman, S. Effect of chewing gums 
containing the probiotic bacterium Lactobacillus reuteri on oral malodour. Acta Odontol. Scand. 
2012, 70, 246–250. 
41. Wang, S.; Zhu, H.; Lu, C.; Kang, Z.; Luo, Y.; Feng, L.; Lu, X. Fermented milk supplemented 
with probiotics and prebiotics can effectively alter the intestinal microbiota and immunity of host 
animals. J. Dairy Sci. 2012, 95, 4813–4822. 
42. Allen, S.J.; Wareham, K.; Bradley, C.; Harris, W.; Dhar, A.; Brown, H.; Foden, A.; Cheung, W.Y.; 
Gravenor, M.B.; Plummer, S.; et al. A multicentre randomised controlled trial evaluating 
lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people 
admitted to hospital: The PLACIDE study protocol. BMC Infect. Dis. 2012, 12, 108. 
43. Iniesta, M.; Herrera, D.; Montero, E.; Zurbriggen, M.; Matos, A.R.; Marín, M.J.;  
Sánchez-Beltrán, M.C.; Llama-Palacio, A.; Sanz, M. Probiotic effects of orally administered 
Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with 
gingivitis. A randomized clinical trial. J. Clin. Periodontol. 2012, 39, 736–744. 
Nutrients 2013, 5 2547 
 
44. Slawik, S.; Staufenbiel, I.; Schilke, R.; Nicksch, S.; Weinspach, K.; Stiesch, M.; Eberhard, J. 
Probiotics affect the clinical inflammatory parameters of experimental gingivitis in humans. Eur. 
J. Clin. Nutr. 2011, 65, 857–863. 
45. Vandenplas, Y.; de Hert, S.G. Randomised clinical trial: The synbiotic food supplement 
Probiotical vs. placebo for acute gastroenteritis in children. Aliment. Pharmacol. Ther. 2011, 34, 
862–867. 
46. Burton, J.P.; Cowley, S.; Simon, R.R.; McKinney, J.; Wescombe, P.A.; Tagg, J.R. Evaluation of 
safety and human tolerance of the oral probiotic Streptococcus salivarius K12: A randomized, 
placebo-controlled, double-blind study. Food Chem. Toxicol. 2011, 49, 2356–2364. 
47. Krauss-Silva, L.; Moreira, M.E.; Alves, M.B.; Braga, A.; Camacho, K.G.; Batista, M.R.;  
Almada-Horta, A.; Rebello, M.R.; Guerra, F. A randomised controlled trial of probiotics for the 
prevention of spontaneous preterm delivery associated with bacterial vaginosis: Preliminary 
results. Trials 2011, 12, 239. 
48. Hummelen, R.; Changalucha, J.; Butamanya, N.L.; Koyama, T.E.; Cook, A.; Habbema, J.D.; 
Reid, G. Effect of 25 weeks probiotic supplementation on immune function of HIV patients.  
Gut Microbes 2011, 2, 80–85. 
49. Harini, P.M.; Anegundi, R.T. Efficacy of a probiotic and chlorhexidine mouth rinses: A  
short-term clinical study. J. Indian Soc. Pedod. Prev. Dent. 2010, 28, 179–182. 
50. Saxelin, M.; Lassig, A.; Karjalainen, H.; Tynkkynen, S.; Surakka, A.; Vapaatalo, H.; Järvenpää, S.; 
Korpela, R.; Mutanen, M.; Hatakka, K. Persistence of probiotic strains in the gastrointestinal tract 
when administered as capsules, yoghurt, or cheese. Int. J. Food Microbiol. 2010, 144, 293–300. 
51. Hummelen, R.; Changalucha, J.; Butamanya, N.L.; Cook, A.; Habbema, J.D.; Reid, G. 
Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among 
women with HIV. Int. J. Gynaecol. Obstet. 2010, 111, 245–248. 
52. Arroyo, R.; Martín, V.; Maldonado, A.; Jiménez, E.; Fernández, L.; Rodríguez, J.M. Treatment of 
infectious mastitis during lactation: Antibiotics versus oral administration of Lactobacilli isolated 
from breast milk. Clin. Infect. Dis. 2010, 50, 1551–1558. 
53. Grossi, E.; Buresta, R.; Abbiati, R.; Cerutti, R. Clinical trial on the efficacy of a new symbiotic 
formulation, Flortec, in patients with acute diarrhea: A multicenter, randomized study in primary 
care. J. Clin. Gastroenterol. 2010, 44, S35–S41. 
54. Sierra, S.; Lara-Villoslada, F.; Sempere, L.; Olivares, M.; Boza, J.; Xaus, J. Intestinal and 
immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to 
healthy adults. Anaerobe 2010, 16, 195–200. 
55. Sinkiewicz, G.; Cronholm, S.; Ljunggren, L.; Dahlén, G.; Bratthall, G. Influence of dietary 
supplementation with Lactobacillus reuteri on the oral flora of healthy subjects. Swed. Dent. J. 
2010, 34, 197–206. 
56. Mayanagi, G.; Kimura, M.; Nakaya, S.; Hirata, H.; Sakamoto, M.; Benno, Y.; Shimauchi, H. 
Probiotic effects of orally administered Lactobacillus salivarius WB21-containing tablets on 
periodontopathic bacteria: A double-blinded, placebo-controlled, randomized clinical trial.  
J. Clin. Periodontol. 2009, 36, 506–513. 
  
Nutrients 2013, 5 2548 
 
57. Dommels, Y.E.; Kemperman, R.A.; Zebregs, Y.E.; Draaisma, R.B.; Jol, A.; Wolvers, D.A.; 
Vaughan, E.E.; Albers, R. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus 
GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. Appl. 
Environ. Microbiol. 2009, 75, 6198–6204. 
58. Ranganathan, N.; Friedman, E.A.; Tam, P.; Rao, V.; Ranganathan, P.; Dheer, R. Probiotic dietary 
supplementation in patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial 
in Canada. Curr. Med. Res. Opin. 2009, 25, 1919–1930. 
59. Twetman, S.; Derawi, B.; Keller, M.; Ekstrand, K.; Yucel-Lindberg, T.; Stecksen-Blicks, C. 
Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of 
inflammatory mediators in gingival crevicular fluid. Acta Odontol. Scand. 2009, 67, 19–24. 
60. Basu, S.; Paul, D.K.; Ganguly, S.; Chatterjee, M.; Chandra, P.K. Efficacy of high-dose  
Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: A 
randomized controlled trial. J. Clin. Gastroenterol. 2009, 43, 208–213. 
61. Staab, B.; Eick, S.; Knöfler, G.; Jentsch, H. The influence of a probiotic milk drink on the 
development of gingivitis: A pilot study. J. Clin. Periodontol. 2009, 36, 850–856. 
62. Mao, M.; Yu, T.; Xiong, Y.; Wang, Z.; Liu, H.; Gotteland, M.; Brunser, O. Effect of a lactose-free 
milk formula supplemented with bifidobacteria and streptococci on the recovery from acute 
diarrhoea. Asia Pac. J. Clin. Nutr. 2008, 17, 30–34. 
63. Shimauchi, H.; Mayanagi, G.; Nakaya, S.; Minamibuchi, M.; Ito, Y.; Yamaki, K.; Hirata, H. 
Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: A 
randomized, double-blind, placebo-controlled study. J. Clin. Periodontol. 2008, 35, 897–905. 
64. Marcone, V.; Calzolari, E.; Bertini, M. Effectiveness of vaginal administration of Lactobacillus 
rhamnosus following conventional metronidazole therapy: How to lower the rate of bacterial 
vaginosis recurrences. New Microbiol. 2008, 31, 429–433. 
65. Panigrahi, P.; Parida, S.; Pradhan, L.; Mohapatra, S.S.; Misra, P.R.; Johnson, J.A.; Chaudhry, R.; 
Taylor, S.; Hansen, N.I.; Gewolb, I.H. Long-term colonization of a Lactobacillus plantarum 
synbiotic preparation in the neonatal gut. J. Pediatr. Gastroenterol. Nutr. 2008, 47, 45–53. 
66. Mohan, R.; Koebnick, C.; Schildt, J.; Mueller, M.; Radke, M.; Blaut, M. Effects of 
Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, 
calprotectin, and IgA in preterm infants. Pediatr. Res. 2008, 64, 418–422. 
67. Ivory, K.; Chambers, S.J.; Pin, C.; Prieto, E.; Arqués, J.L.; Nicoletti, C. Oral delivery of 
Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin. 
Exp. Allergy 2008, 38, 1282–1289. 
68. Htwe, K.; Yee, K.S.; Tin, M.; Vandenplas, Y. Effect of Saccharomyces boulardii in the treatment 
of acute watery diarrhea in Myanmar children: A randomized controlled study. Am. J. Trop. Med. 
Hyg. 2008, 78, 214–216. 
69. Larsson, P.G.; Stray-Pedersen, B.; Ryttig, K.R.; Larsen, S. Human lactobacilli as supplementation 
of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month,  
double-blind, randomized, placebo-controlled study. BMC Womens Health 2008, 8, 3. 
70. Hatakka, K.; Ahola, A.J.; Yli-Knuuttila, H.; Richardson, M.; Poussa, T.; Meurman, J.H.; Korpela, R. 
Probiotics reduce the prevalence of oral candida in the elderly—A randomized controlled trial.  
J. Dent. Res. 2007, 86, 125–130. 
Nutrients 2013, 5 2549 
 
71. Basu, S.; Chatterjee, M.; Ganguly, S.; Chandra, P.K. Effect of Lactobacillus rhamnosus GG in 
persistent diarrhea in Indian children: A randomized controlled trial. J. Clin. Gastroenterol. 2007, 
41, 756–760. 
72. Henker, J.; Laass, M.; Blokhin, B.M.; Bolbot, Y.K.; Maydannik, V.G.; Elze, M.; Wolff, C.; 
Schulze, J. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in 
infants and toddlers. Eur. J. Pediatr. 2007, 166, 311–318. 
73. Sugawara, G.; Nagino, M.; Nishio, H.; Ebata, T.; Takagi, K.; Asahara, T.; Nomoto, K.; Nimura, Y. 
Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary 
cancer surgery: A randomized controlled trial. Ann. Surg. 2006, 244, 706–714. 
74. Krasse, P.; Carlsson, B.; Dahl, C.; Paulsson, A.; Nilsson, A.; Sinkiewicz, G. Decreased gum 
bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri. Swed. Dent. J. 2006, 30, 
55–60. 
75. Margreiter, M.; Ludl, K.; Phleps, W.; Kaehler, S.T. Therapeutic value of a Lactobacillus gasseri 
and Bifidobacterium longum fixed bacterium combination in acute diarrhea: A randomized, 
double-blind, controlled clinical trial. Int. J. Clin. Pharmacol. Ther. 2006, 44, 207–215. 
76. Olivares, M.; Díaz-Ropero, M.A.; Gómez, N.; Lara-Villoslada, F.; Sierra, S.; Maldonado, J.A.; 
Martín, R.; López-Huertas, E.; Rodríguez, J.M.; Xaus, J. Oral administration of two probiotic 
strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances 
the intestinal function of healthy adults. Int. J. Food Microbiol. 2006, 107, 104–111. 
77. Sarker, S.A.; Sultana, S.; Fuchs, G.J.; Alam, N.H.; Azim, T.; Brüssow, H.; Hammarström, L. 
Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of 
nonrotavirus diarrhea in children from Bangladesh. Pediatrics 2005, 116, e221–e228. 
78. Schrezenmeir, J.; Heller, K.; McCue, M.; Llamas, C.; Lam, W.; Burow, H.; Kindling-Rohracker, M.; 
Fischer, W.; Sengespeik, H.C.; Comer, G.M.; et al. Benefits of oral supplementation with and 
without synbiotics in young children with acute bacterial infections. Clin. Pediatr. (Phila.) 2004, 
43, 239–249. 
79. Reid, G.; Burton, J.; Hammond, J.A.; Bruce, A.W. Nucleic acid-based diagnosis of bacterial 
vaginosis and improved management using probiotic lactobacilli. J. Med. Food. 2004, 7, 223–228. 
80. Morelli, L.; Zonenenschain, D.; Del Piano, M.; Cognein, P. Utilization of the intestinal tract as a 
delivery system for urogenital probiotics. J. Clin. Gastroenterol. 2004, 38, S107–S110. 
81. Reid, G.; Charbonneau, D.; Erb, J.; Kochanowski, B.; Beuerman, D.; Poehner, R.; Bruce, A.W. 
Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal 
flora: Randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol. Med. 
Microbiol. 2003, 35, 131–134. 
82. Arvola, T.; Laiho, K.; Torkkeli, S.; Mykkänen, H.; Salminen, S.; Maunula, L.; Isolauri, E. 
Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory 
infections: A randomized study. Pediatrics 1999, 104, e64. 
83. Schulz, K.F.; Altman, D.G.; Moher, D.; CONSORT Group. CONSORT 2010 statement: Updated 
guidelines for reporting parallel group randomised trials. J. Clin. Epidemiol. 2010, 63, 834–840. 
84. Montané, E.; Vallano, A.; Vidal, X.; Aguilera, C.; Laporte, J.R. Reporting randomised clinical 
trials of analgesics after traumatic or orthopaedic surgery is inadequate: A systematic review. 
BMC Clin. Pharmacol. 2010, 10, 2. 
Nutrients 2013, 5 2550 
 
85. Thomson Reuters. Available on line: http://www.thomsonreuters.com/products_services/science/ 
science_products/a-z/journal_citation_reports/ (accessed on 14 May 2013). 
86. Teughels, W.; van Essche, M.; Sliepen, I.; Quirynen, M. Probiotics and oral healthcare. 
Periodontol. 2000 2008, 48, 111–147. 
87. Campus, G.; Cagetti, M.G.; Sale, S.; Petruzzi, M.; Solinas, G.; Strohmenger, L.; Lingström, P. Six 
months of high-dose xylitol in high-risk caries subjects—A 2-year randomised, clinical trial.  
Clin. Oral Investig. 2013, 17, 785–791. 
88. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the 
substantiation of health claims related to Lactobacillus reuteri ATCC 55730 and ―natural defence‖ 
(ID 905) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2010, 8, 1805. 
89. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the 
substantiation of health claims related to Lactobacillus rhamnosus ATCC 53103 (LGG) and 
―gastro-intestinal health‖ (ID 906) and maintenance of tooth mineralisation (ID 3018) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011, 9, 2233. 
90. Bath, F.J.; Owen, V.E.; Bath, P.M. Quality of full and final publications reporting acute stroke 
trials. A systematic review. Stroke 1998, 29, 2203–2210. 
91. Garfield, E. Journal impact factor: A brief review. Can. Med. Assoc. J. 1999, 161, 979–980. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
